MMP9 and cancer: Furthermore, similar to combining genetic knockdown with pharmacologic inhibition, using a PNA to block to the recently described EZH2-interactiing domain of HOTAIR16 and disrupt the HOTAIR-EZH2 interaction resensitizes cancer cells to clinically relevant cytotoxic chemotherapies (Figs 1E,F, 2, 3 and 4), reduces cell invasion (Fig. 2A,B) and decreases NF-κB transcriptional activity (Fig. 3B) and IL-6 and MMP-9 expression in vivo (Fig. 4F,G).